We report on a molecular cytogenetic characterization of 15q26 deletion and 2q37.1 duplication in a fetus presenting with intrauterine growth restriction (IUGR), diaphragmatic hernia, multicystic kidneys, left kidney pyelectasis, and clubfeet. A terminal 15q26 deletion and a terminal 2q duplication of at least 10 and 9 Mb, respectively, derived from a maternal translocation, were found. The 15q26 deletion represents a contiguous gene deletion syndrome mainly characterized by IUGR, congenital diaphragmatic hernia, and less frequently kidney defects. This deletion encompasses the and genes, known to lead to fetal growth retardation syndrome. However, kidney malformations are less well known in such conditions, and to the best of our knowledge, no candidate gene has been proposed to date. Here, we review the literature of the 15q26 deletion syndrome and suggest that hypoplastic and multicystic kidneys, the most commonly observed anomalies in this condition, should be considered in the prenatal diagnosis setting. Based on COUPTF2 protein function, we hypothesize that its haploinsufficiency might be responsible for the renal pathology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683954PMC
http://dx.doi.org/10.1055/s-0037-1602696DOI Listing

Publication Analysis

Top Keywords

15q26 deletion
16
multicystic kidneys
12
2q371 duplication
8
review literature
8
diaphragmatic hernia
8
deletion syndrome
8
deletion
6
15q26
5
array characterization
4
characterization prenatally
4

Similar Publications

Identification of copy-number variants in patients with overgrowth disorders.

Clin Genet

November 2024

CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.

Overgrowth syndromes (OGS) comprise a heterogeneous group of disorders whose main characteristic is that the weight, height or the head circumference are above the 97th centile or 2-3 standard deviations above the mean for age, gender, and ethnic group. Several copy-number variants (CNVs) have been associated with the development of OGS, such as the 5q35 microdeletion or the duplication of the 15q26.1-qter, among many others.

View Article and Find Full Text PDF

Develop a clinical and genetic characterization, in a group of small-for-gestational-age (SGA) patients who did not experience catch-up growth In an ambispective cohort study with (SGA) patients. These patients received one treatment with growth hormone (GH) over 14 years. This study analyzes their response to treatment and conducts a genetic analysis in order to identify cases with specific phenotypic and auxological characteristics, defined as presenting two or more dysmorphic traits and/or a stature below -3 SDS (standard deviation score).

View Article and Find Full Text PDF

In the past, there were no easily distinct and recognizable features as a guide for precise clinical and genetic diagnosis of cases with chromosome microdeletions involving 15q26 including . The present study analysed the clinical data and collected venous blood samples from a pediatric patient and his healthy family members for DNA testing. The whole-exome sequencing was performed by the next-generation sequencing (NGS).

View Article and Find Full Text PDF
Article Synopsis
  • Short stature linked to IGF-1 receptor (IGF1R) gene alterations, identified as small-for-gestational-age (SGA) short stature, is not well understood in terms of prevalence and clinical traits, with no dedicated treatments in Japan.
  • An analysis of 13 patients revealed that cases with chromosome 15q26.3 deletions presented more severe growth issues, while those with IGF1R gene variants showed no distinct symptoms; only a few had elevated serum IGF1 levels.
  • Six patients receiving growth hormone (GH) therapy had improved growth without side effects or increased IGF1 levels, highlighting the importance of genetic testing and more research on GH treatment for this condition.
View Article and Find Full Text PDF

Individuals with severe and treatment-resistant obsessive-compulsive disorder (trOCD) represent a small but severely disabled group of patients. Since trOCD cases eligible for deep brain stimulation (DBS) probably comprise the most severe end of the OCD spectrum, we hypothesize that they may be more likely to have a strong genetic contribution to their disorder. Therefore, while the worldwide population of DBS-treated cases may be small (~300), screening these individuals with modern genomic methods may accelerate gene discovery in OCD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!